HAVN Life Announces Gary Leong’s Appointment to Board of Directors
Mr. Leong brings with him a wealth of scientific and regulatory experience
Vancouver, BC – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company developing natural health products and innovative therapies to support brain health and enhance the capabilities of the mind, is pleased to announce the appointment of Mr. Gary Leong to its Board of Directors. Concurrently, Mr. Leong has stepped down as HAVN Life’s Chief Science Officer, shifting his focus to an advisory role within the organization.
Mr. Leong has been instrumental in the regulatory development and launch of HAVN Life’s Retail Division, formulating its portfolio of natural health products, launched in June of 2021. Gary Leong has more than thirty years of experience in the pharmaceutical and natural health product industries. Mr. Leong is currently acting as the Director of Quality and Compliance at the privately Licensed Cannabis Processor, Tricanna Industries Inc. He was the Chief Scientific Officer at Aphria Inc. in Leamington, ON from its inception in 2014 to 2019, where he established and oversaw the Quality Assurance, Quality Control, Regulatory Affairs and Research and Development functions. Prior to this, he served as the Chief Scientific Officer of Jamieson Laboratories in Windsor, ON for fourteen years. He has also managed the scientific and quality functions for Boehringer Ingelheim, Natural Factors Nutritional Products Ltd. and Nordion. Gary holds a B.Sc. in Chemistry and a M.B.A. in Quality Management and has served on the Board of Directors of several public companies and research societies, as well as an advisor to several Canadian government regulatory advisory committees.
“Mr. Leong has been a key member of the HAVN Life Sciences leadership team, especially with respect to launching HAVN Life’s Retail Division, and we are happy to welcome him to our Board of Directors where his scientific and regulatory experience will help us make strategic decisions for both our retail and psychedelic businesses as we move forward into further growth in 2022,” says HAVN Life’s Chairman of the Board, Mr. Vic Neufeld. “We thank him for his work and look forward to benefiting from his expertise as a Board Member,” he added.
HAVN Life Sciences closes out its inaugural year with an eye towards expanding its global retail presence in 2022.
###
On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer
About HAVN Life Sciences Inc.
HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind.
Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, HAVN Life offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.
Purchase our products and find out more at yourhavnlife.com, and follow us on Facebook, Twitter, Instagram and Youtube.
Contact:
Investor Relations: ir@havnlife.com 604 687-7130
Media: savi@emergence-creative.com 647 896-8078
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release